



1FL)

IN THE UNITED STATES PATENTAND TRADEMARK OFFICE

In re Application of:
Henrik PEDERSEN

(O)
Examiner:

Serial No.: 11/522,17/1

Filed: November 4, 2005

For: GENE SHUFFLING BY TEMPLATE)

SWITCHING

Art Unit:

Washington, D.C.

Docket No.: PEDERSEN11

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- 1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:
- [] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application. See 37 CFR 1.97(b).
- [X] B. before the mailing date of a first office action on the merits. See 37 CFR 1.97(b).
- [] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "i"

below). See 37 CFR 1.97(c).

- [] i. Counsel certifies that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- [] ii. A check for the fee set forth in 1.17(p), presently believed to be \$180, is enclosed (check no. _____).
- [] D. after (A), (B) and (C) above, but before payment of the issue fee. Applicant petitions under 37 C.F.R. 1.97(d) for consideration of this IDS. A check for the fee set forth in 1.17(i)(1), presently believed to be \$130 is enclosed (check no. ________). Counsel certifies that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- [] E. As a submission in accordance with the transitional procedure for limited examination after final rejection pursuant to 37 CFR \$1.129(a). Pursuant to MPEP \$706.07(g), page 700-46, col. 2 (February 2000), this IDS is treated as if filed with a period set forth in 37 CFR \$1.97(b)

and considered without the petition and petition fee required by 1.97(d).

- 2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document is attached, except as explained below.
- [X] While an IDS filed under §1.97 must contain a "list of all patents, publications or other information submitted for consideration by the Office", see §1.98(a) (1), the only requirement for the list is that it provide the information set forth in §1.98(b). There is no requirement that a form PTO-1449 be used (MPEP §609 merely says that use of this form is "encouraged"). Counsel has used a list provided to him by Applicants, and not transferred the information to a PTO-1449, to avoid the risk of any inadvertent error in transferring the information.
- [] A. Documents ______ are deemed substantially cumulative to documents ______, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- [] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

[insert serial number/filing date]

Applicants identify these documents by attaching hereto copies of the form PTO-892s and PTO-1449s from the files of the prior applications or a fresh PTO-1449 listing these documents, and request that they be considered and made of record in accordance

with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application. If copies of any of these documents cannot be found in the files of the prior applications, the Examiner is requested to so notify counsel before taking action in this case, so replacement copies can be submitted. While an IDS filed under §1.97 must contain a "list of all patents, publications or other information submitted for consideration by the Office", see \$1.98(a) (1), the only requirement for the list is that it provide the information set forth in \$1.98(b). There is no requirement that a form PTO-1449 be used (MPEP §609 merely says that use of this form is "encouraged") and no prohibition on submitting a copy of a form PTO-1449 or form PTO-892 from a prior case. Indeed, the re-use of such forms is desirable as it avoids error in transferring the information, and evidences that the reference was considered in a prior application. A previously accepted PTO-1449, or an examiner-prepared PTO-892, necessarily complies with §1.98(b).

| | T | L | | | ., | 1 | ~ · · · · · · · · · · · · · · · · · · · | | | 5- | | ,~,. |
|-----------|---|----|------|---------------------|---------|----------|---|--------|------|-------|------|-------|
| | [|] | 3. | Docume | nts | | are | not | in | the | Eng | lish |
| language. | | In | acc | ordance | with 1 | .98(c), | Appl | icant | s s | tate | : | |
| | [|] | doc | uments ₋ | ******* | al | ready | y con | tai | n an | Eng | lish |
| | | | lan | guage al | stract | , summa | ry or | clai | m s | et. | | |
| | [|] | a p | ublicly | availa | ble abs | tract | isa | atta | ched | to | each |
| | | | of | documen | | | , and | d the | sou | urce | of | each |
| | | | abs | tract is | s indic | ated th | ereon | | | | | |
| | [|] | doc | uments . | | | are p | atent | cs (| or pu | ıbli | shed |
| | | | pate | ent appl | licatio | ns for | which | cour | ter | part | Eng | lish |
| | | | lang | guage pa | tents o | or pater | t app | olicat | cion | s ex | ist, | and |
| | | | are | enclose | ed, as | follows | : | | | | | |
| | | | | Foreign | Lang. | Doc.# | E | nglis | h L | ang. | Doc | : . # |
| | | | | | | | | | | | | |

[insert]

[insert]

- at least the pertinent portions of documents _____, and copies are attached.
- [] A concise explanation of the relevance of documents _____ is found in the attached search report from the _____ Patent Office (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).
- [] A concise explanation of the relevance of documents _____ is set forth as follows: [Insert concise explanation of relevance]
- 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 5. Other information being provided for the examiner's consideration follows:

[insert other information]

- 6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in \$1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.
- 7. The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant

By:

Iver P. Cooper Reg. No. 28,005

624 Ninth Street, N.W. Washington, D.C. 20001 Telephone: (202)628-5197 Facsimile: (202)737-3528

IPC:ses

G:\ipc\g-i\hoib\Pedersen11\IDSIPC2.doc

| FORM PTO-1- PATENT AND | TRADI | EMARK | OFFIC | E | 1 | | | 4 | ATTY DOCKET NO: PEDERSEN11 | | | SERIAL NO: 1/522,171 10 | |
|---|-----------------|----------|--------|----------|--|-----|------|--------|-------------------------------|-------------------|-------|-------------------------------|---------------------------|
| LIST OF DOC (Use several s | UMENT | S CITE | D BY A | PPLICA | A STATE OF THE PARTY OF THE PAR | JAN | 27 | 2006 | S APPLICANT:Nuevolution A/S | | | | |
| | | | | | | ADE | MARK | OFFICE | FILING DATE: November 4, 2005 | | | GROUP: | |
| U.S. PATENT DOCUMENTS (include at least patentee, patent number and issue date) | | | | | | | | | | | | | |
| EXAMINER INITIAL | DOCUMENT NUMBER | | | | | | | | DATE | PATENTEE | CLASS | SUB- CLASS | FILING DATE IF APPROP. |
| | | | | | | | | | - | | - | | |
| | | | | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country) | | | | | | | | | | | | | |
| | | | | | | | | | · | date and country/ | | | |
| | DOCUMENT NUMBER | | | | | | ER | | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES/NO |
| | CN | 02 | 1 | 0 | 3 | 0 | 0 | # | 27 Dec 2002 | PCT | | CLAGO | TES/NO |
| | со | 02 | 1 | 0 | 2 | θ | 2 | 4 | 27 Dec 2002 | PCT | | | |
| | СР | 03 | 0 | 7 | 8 | 6 | 2 | 5 | 25 Sept 2003 | PCT | | - | |
| | Cσ | 20 | 04 | 01 | 3 | 6 | 7 | 4 | 12 Feb 2004 | PCT | | | |
| | CR | 20 | 04 | 11 | 0 | 9 | 6 | 4 | 23 12 2004 | PCT | | | |
| | cs | 20 | 04 | 02 | 4 | • | 2 | 9 | 25 March 2004 | PCT | | | |
| | CT | 20 03 | 04 | 05 7 | 6 | 9 | 9 | 4 | 8 July 2004 | PCT | | | |
| | CU | 03 | 0 | ′ | 8 | 4 | 4 | 5 | 25 Sept. 2003 | PCT |] | | |
| | CV | 03 | 0 | 7 | 8 | 6 | 2 | 9 | 25 Sept 2003 | PCT | | | |
| | cw | 03 | 0 | 7 | 8 | 0 | 5 | 9 | 25 Sept 2003 | PCT | | | |
| | СХ | 03 | 0 | 7 | 8 | 4 | 4 | 0 | 25 Sept 2003 | PCT | | | |
| | CY | 03 | 0 | 7 | 8 | 6 | ′2 | 7 | 25 Sept 2003 | PCT | | | |
| | CZ | 20 | 04 | 07 | 4 | 5 | 0 | 1 | 2 Sept 2004 | PCT | | | |
| | DA DB | 20 20 | 04 | 07 08 | 3 | 4 | 2 | 9 | 2 Sept 2004 30 Sept | PCT PCT | | | |
| | | | | | | | | | 2004 | FCI | | | |
| | DC | 20 | 04 | 08 | 8 | θ | 2 | 5 | 13 May 2004 | PCT | | | |
| | DD | 20 | 04 | 00 | 1 | C | 4 | 2 | 30 Dec 2003 | PCT | | | |
| | DE | 20 | 05 | 00 | 3 | 7 | 7 | 8 | 13 Jan 2005 | PCT | | | |
| | DF | 0 | 2 | 3 | 8 | 7 | 5 | 7 | 16 May 2002 | PCT . | | | |
| | DG | 9 | 8 | 4 | 2 | 8 | 3 | 2 | 1 Oct 1998 | PCT | | | 4 |
| | DH | 9 | 8 | 0 | 1 | 5 | 8 | 1 | 15 Jan 1998 | PCT | | | |
| | | | | L | 1 | | | ll | | | | | |
| EXAMINER | | | | | | | | | | DATE CONSIDERED | | | |
| | | | | | | | | | | | | | |

| | | U.S. DEPARTMENT OF COMMERCE | ATTY D | OCKET NO: PEDERSEN11 | SERIAL NO: 11/522,171 | | | | | | | |
|----------|----------|---|----------------------------|--|--------------------------------|--|--|--|--|--|--|--|
| | | rs CITED BY APPLICANT ats if necessary) | APPLICANT: Nuevolution A/S | | | | | | | | | |
| | | | FILING | DATE: November 4, 2005 | GROUP: | | | | | | | |
| OTHER DO | CUME | NTS (include author, title, name of public | | | | | | | | | | |
| | DI | Negroni M et al. "Recombination during of Molecular Biology, vol 286, no.1 12 | | ansciption: an evaluation of the role of the r p15-31 | nucleocapsid protein". Journal | | | | | | | |
| | DJ | Moumen Abdeladim et al. "The HIV-1 repeated sequence R as a robust hot-spot for copy-choice recombination" Nucleic acids research, vol. 29, no. 18, 15 September 2001, p 3814-3821 | | | | | | | | | | |
| | DK | Negroni M et al. "Homologous recombination prompted by reverse transcriptase during copying of two distinct RNA templates" Proceedings of the National Academy of Sciences of the United States, vol. 92, no. 15, 1995, p 6971-6975 | | | | | | | | | | |
| | DL | Peliska, J et al. "Fidelity of in vitro DANN strand transfer reactions catalyzed by HIV-1 reverse transciptase". Biochemistry, vol. 33, no. 13, 1994, p 3890-3895 | | | | | | | | | | |
| | DM | Peliska, J et al. "Mechanism of DANN strand transfer reactions catalyzed by HIV-1 reverse transcriptase". Science vol. 258, no. 5058, 1992, p1112-1118 | | | | | | | | | | |
| | DN | Gish, G et al. "DNA and RNA sequence determination based on phosphorothioate". chemistry Science, American Association for advancement of science, US, vol. 240, 1988, p 1520-1522 | | | | | | | | | | |
| | DO | Hwang, CK et al. "Dynamic copy choice: steady state between murine leukemia virus polymerase and polymerase- dependent RNase H activity determines frequency of in vivo template switching". Proceedings of the National Academy of Sciences of the Unite States, vol. 98, no. 21, 9 Oct 2001 p 12209-12214 | | | | | | | | | | |
| | DP | Brakmann, S et al. "An error-prone T7 RNA polymerase mutant generated by directed evolution Chembiochem". A European journal of Chemical Biology. 2 Mar 2001, vol. 2, no. 3, 2 March 2001 p212-219 | | | | | | | | | | |
| | DQ | DeStefano JJ et al. "Determinants of the Rnase H cleavage specificity of human immunodeficiency virus reverse transcriptase". Nucleic acids research, vol 21, no. 18, 1993, p 4330-4338 | | | | | | | | | | |
| | DR | Wu Weimin et al. "Strand Transfer Mediated by Human Immunodeficiency Virus Reverse Transcriptase in Vitro is Promoted by Pausing and Results in Misincorporation". Journal of Biological Chemistry, vol. 270, no. 1, 1995, p325-332 | | | | | | | | | | |
| | DS | Svarovskaia ES et al. "Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switching". Journal of Virology, vol. 74, no. 15, Aug 2000, p7171-7178. | | | | | | | | | | |
| | DT | Negroni, M et al. "Copy-choice recombination by reverse transcriptases: Reshuffling of genetic markers mediated by RNA chaperones". Proceedings of the National Academy of Sicences of the United States, vol. 97, no. 12, 6 June 2000, p 6385-6390 | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| EXAMINER | <u> </u> | | DATE CONSIDERED | | | | | | | | | |
| EXAMINER | | al if reference considered. Draw line through next communication to applicant. | ugh citatio | n if not in conformance <u>and</u> not considered. | Include copy of this form | | | | | | | |